Hepatic arterial infusion of irinotecan and EmboCept® S results in high tumor concentration of SN-38 in a rat model of colorectal liver metastases
- 29 Downloads
Intraarterial chemotherapy for colorectal liver metastases (CRLM) can be applied alone or together with embolization particles. It remains unclear whether different types of embolization particles lead to higher intratumoral drug concentration. Herein, we quantified the concentrations of CPT-11 and its active metabolite SN-38 in plasma, liver and tumor tissue after hepatic arterial infusion (HAI) of irinotecan, with or without further application of embolization particles, in a rat model of CRLM. Animals underwent either systemic application of irinotecan, or HAI with or without the embolization particles Embocept® S and Tandem™. Four hours after treatment concentrations of CPT-11 and SN-38 were analyzed in plasma, tumor and liver samples by high-performance liquid chromatography. Additionally, DNA-damage and apoptosis were analyzed immunohistochemically. Tumor tissue concentrations of SN-38 were significantly increased after HAI with irinotecan and EmboCept® S compared to the other groups. The number of apoptotic cells was significantly higher after both HAI with irinotecan and EmboCept® S or Tandem™ loaded with irinotecan compared to the control group. HAI with irinotecan and EmboCept® S resulted in an increased SN-38 tumor concentration. Both HAI with irinotecan and EmboCept® S or Tandem™ loaded with irinotecan were highly effective with regard to apoptosis.
KeywordsHepatic arterial infusion Irinotecan SN38
The authors thank Birgit Jünemann who helped to establish the immunohistochemistry staining.
A Kauffels salary during the time of the study and part of the study itself has beend funded by the Else Kröner-Fresenius-Stiftung (EKFS), Bad Homburg v.d.H, Germany, due to a scholarship. The cost for HPLC-analyses in Vienna has been covered by PharmaCept GmbH, Berlin, Germany.
Compliance with Ethical Standards
Conflict of interest
A Kuthning works for PharmaCept GmbH, Berlin. All other authors declare no potential conflict of interest.
All procedures performed in studies involving animals were in accordance with the ethical standards of the institution at which the studies were conducted (Niedersächsisches Landesamt für Verbraucherschutz und Lebensmittelsicherheit, ethics approval number 14/1610).
- 3.McAuliffe JC, Qadan M, D’Angelica MI (2015) Hepatic resection, hepatic arterial infusion pump therapy, and genetic biomarkers in the management of hepatic metastases from colorectal cancer. J Gastrointest Oncol 6:699–708Google Scholar
- 6.DʼAngelica MI, Correa-Gallego C, Paty PB, Cercek A, Gewirtz AN, Chou JF et al (2015) Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. Ann Surg 261:353–360CrossRefGoogle Scholar
- 11.Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A (2001) Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7:2182–2194Google Scholar
- 16.Institute of Laboratory Animal Resources, National Research Council (1996) Guide for the care and use of laboratory animals, 8th edn. NIH Guide, UKGoogle Scholar
- 18.Sperling J, Brandhorst D, Schäfer T, Ziemann C, Benz-Weißer A, Scheuer C et al (2013) Liver-directed chemotherapy of cetuximab and bevacizumab in combination with oxaliplatin is more effective to inhibit tumor growth of CC531 colorectal rat liver metastases than systemic chemotherapy. Clin Exp Metastasis 30:447–455CrossRefGoogle Scholar
- 19.Sperling J, Schäfer T, Benz-Weißer A, Ziemann C, Scheuer C, Kollmar O et al (2013) Hepatic arterial infusion but not systemic application of cetuximab in combination with oxaliplatin significantly reduces growth of CC531 colorectal rat liver metastases. Int J Colorectal Dis 28:555–562CrossRefGoogle Scholar
- 20.Eder I, Czejka M, Schueller J, Zeleny U (2000) Clinical pharmacokinetics (PHK) and metabolism of irinotecan (IRINO) during mono- and polychemotherapy with 5-Fluorouracil/Leucovorin (5FU/LV) and Docetaxel (DOCE). Eur J Pharm Sci 11:23Google Scholar
- 21.Slatter JG, Schaaf LJ, Sams JP, Feenstra KL, Johnson MG, Bombardt PA et al (2000) Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. Drug Metab Dispos 28:423–433Google Scholar
- 22.Czejka M, Kiss A, Koessner C, Terkola R, Ettlinger D, Schueller J (2011) Metabolic activation of irinotecan during intra-arterial chemotherapy of metastatic colorectal cancer. Anticancer Res 31:3573–3578Google Scholar
- 23.Basu S, Zeng M, Yin T, Gao S, Hu M (2016) Development and validation of an UPLC-MS/MS method for the quantification of irinotecan, SN-38 and SN-38 glucuronide in plasma, urine, feces, liver and kidney: application to a pharmacokinetic study of irinotecan in rats. J Chromatogr B Analyt Technol Biomed Life Sci 1015–1016:34–41CrossRefGoogle Scholar
- 27.Thomas C, Nijenhuis AM, Timens W, Kuppen PJ, Daemen T, Scherphof GL (1993) Liver metastasis model of colon cancer in the rat: immunohistochemical characterization. Invasion Metastasis 13:102–112Google Scholar
- 31.Seelig MH, Leible M, Sänger J, Berger MR (2004) Chemoembolization of rat liver metastasis with microspheres and gemcitabine followed by evaluation of tumor cell load by chemiluminescence. Oncol Rep 11:1107–1113Google Scholar
- 36.Oda M, Yokomori H, Han JY (2003) Regulatory mechanisms of hepatic microcirculation. Clin Hemorheol Microcirc 29:167–182Google Scholar
- 37.Koo A, Liang IY, Cheng KK (1975) The terminal hepatic microcirculation in the rat. Q J Exp Physiol Cogn Med Sci 60:261–266Google Scholar